

Comparison of Reverse Transcriptase Loop-Mediated Isothermal Amplification and Reverse Transcriptase Polymerase Chain Reaction for Detection of Prostate Specific Antigen

Mohammad Amin Almasi^{*1}, Marya Esmaili²

ABSTRACT

35

1. Young Researchers and Elites Club, North Tehran Branch, Islamic Azad University, Tehran, Iran.
2. MSc. Student, Microbiology, University of Zanjan and Expert Laboratory Research Unit of Keshtodam-Dashband Co., Boukan, Iran.

*Corresponding Authors:

Mohammad Amin Almasi, PhD
Young Researchers and Elites Club, North Tehran Branch, Islamic Azad University, Tehran, Iran.
Tel: (+98)9146232765
Fax: (+98)4446270539
Email: mohammadaminalmasi.biotech@gmail.com

Background: Research shows that prostate cancer ranks second among the top five most common cancers in men. It has been confirmed that when circulating Prostate Specific Antigen (PSA) transcripts are successfully detected, prostate cancer cells can be diagnosed at an early stage. A reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) assay was developed and compared to reverse transcriptase polymerase chain reaction (RT-PCR) assay for detection of PSA.

Methods: 47 patients, including 30 patients with prostate cancer, 15 with Benign Prostate Hyperplasia (BPH) and 2 healthy subjects as negative controls were included in this study. The prostate cancer cell lines (PC3 and LNCaP) of two patients were included in the study as positive controls. Next, RNA was extracted from fresh samples and a first strand cDNA synthesis kit was applied for the synthesis of cDNA. The human prostate specific antigen gene was used to design specific primers.

Results: The results indicated that the control subjects and participants suffering from BPH were not positive. 13 out of 15 (86.6%) patients suffering from localized cancer were PSA positive. PSA positive results were observed among all 15 metastatic patients and positive controls (100%). RT-LAMP is an advantageous method because it is highly sensitive (1000-fold), quite cheap, user-friendly, and safe; in addition, it can be quickly performed by visual detection using GineFinder™ dye in a water bath.

Conclusion: RT-LAMP technique can be simply and reliably applied with the aid of basic instruments, and its results can be visually inspected in laboratory studies.

Keywords: Benign prostate hyperplasia, Prostate cancer, Prostate specific antigen, RT-LAMP assay, RT-PCR assay



2019; 11(1):35-44

www.bccrjournal.com

INTRODUCTION:

A large number of men die in the United States due to prostate cancer each year¹. Following lung cancer, prostate cancer has become the most rampant cancer in men; every year, up to 300,000 new cases of prostate cancer are reported worldwide^{2,3}. It is believed that measuring serum prostate specific antigen (PSA) levels help diagnose prostate cancer at an earlier stage⁴. There is no doubt that PSA successfully detects Prostate Cancer (CaP) in men, but elevated levels of PSA are also reported in men diagnosed with Benign Prostate Hyperplasia (BPH) and other prostate disorders⁵. Thus, it is necessary to use specific molecular markers to differentiate between CaP and other non-malignant diseases. It has been reported that if circulating PSA transcripts are successfully detected, prostate cancer cells could quickly be identified^{6,7}. Prostate epithelial cells produce PSA; it is a 34 kDa serine protease, which is classified as the third member of the human glandular kalikrein family hk1, hk2 and hk3⁸. High levels of hk2 expression has been observed in the prostate⁹. At concentrations of 0.5-3 mg/ml (i.e., about 1 million times the concentration seen in plasma), PSA enters the seminal fluid¹⁰. Following ejaculation, PSA aids in dissolving gel-forming proteins by digesting seminogelin 1, seminogelin 2 and fibronectin, leading to a consequent release of sperm; this process is believed to be necessary for sperm function¹¹. PSA release is decreased by natural barriers (including the epithelial and basal cell layer as well as the basement membrane) in the prostate of healthy individuals prostate. Disruption of the basement membrane and the basal cell layer occurs in prostate carcinoma¹². Therefore prostate epithelial cells become disorganized, possibly permeating the nearby stroma. Consequently, higher levels of PSA are secreted into the blood of prostate cancer patients¹³. Polymerase chain reaction (PCR)-based assays are the

best alternative to PSA definitive diagnosis; however, its usefulness may be limited by its need for trained staff working with reagents and equipment in a professional operating space^{14,15}. Recently, isothermal amplification methods providing simple and cost-effective molecular tests in low resource settings have been developed, with very high demand¹⁶. Loop-mediated isothermal amplification (LAMP) is one of these methods, which has been widely adopted today. In a single-step reaction, it can provide amplification of 10⁹ copies out of a few copies of the target molecule in less than an hour, even in the presence of large amounts of non-target DNA¹⁷. LAMP can be thwarted by the Bst DNA polymerases (Thermostable enzyme isolated from *Bacillus smithii* bacteria) commonly present in clinical samples and insects as they are more tolerant to the inhibitors¹⁸. Nevertheless, amplification based on LAMP assay can be simply done via visual detection of turbidity created by magnesium pyrophosphate precipitation, intercalating dye fluorescence, or color variations of metal-sensitive indicators by setting a simple electric device like a water bath or heat block at a constant temperature¹⁹. In the present study, we developed a RT-LAMP assay based on the human prostate specific antigen gene of PSA via a visualized system of detection. We also evaluated the efficiency, speed and sensitivity of RT-LAMP for PSA and compared its performance to RT-PCR.

METHODS:

Patients and Samples

By studying clinical and pathological records and focusing on adenocarcinoma of the prostate or BPH at the urology clinics of Shariati, Mehrad and Sina Hospitals, Tehran University of Medical Sciences, Iran, all the patients participating in the study (excluding control subjects) were selected. The study population consisted of 47 patients (15 with localized cancer, 15 with metastatic and 15 with BPH) as well as 2 healthy subjects (1 female and 1 male) as negative controls; their mean

age was 65.2 years (ranging from 50-80). The Iranian Pasteur Institute provided the study with two human prostate cancer cell lines, PC3 and LNCaP, which were used as positive controls. Biopsy was performed on all the patients (excluding the control subjects) due to their abnormal digital rectal exam (DRE) and high serum PSA level. Blood samples were taken (six ml peripheral blood) from all patients either immediately before the radical prostatectomy in the operation room or before biopsy; sodium citrate was applied to treat the blood samples. Following the International Prostate Symptom Score (IPSS) standard, a questionnaire was administered to the patients. Centrifuge was performed on the freshly obtained samples for 15 min at 10000 rpm. The next step was transferring the buffy coat to a new tube; an equal volume of phosphate buffer saline (PBS) was used once in order to wash the buffy coat.

RNA extraction and cDNA synthesis

Some minor modifications were made after the process of total RNA extraction of the samples²⁰. A first-strand cDNA synthesis kit (Roche Inc., GMBH, Germany) was used for cDNA synthesis. Following the kit instructions, a small amount of reaction mix was achieved; it contained 2 µl dithiothreitol (DTT), 4 µl 5x buffer, 1 µl dNTP (10 mM), 1 µl oligo deoxy thymidine (dt), 1 µl random hexamer, 0.15 µl RNase inhibitor; 1.5 µl moloney murine leukemia virus reverse transcriptase

enzyme (MMLV) and approximately one microgram total RNA. Following the addition of H₂O, the volume of the mixture reached 25 µl. Synthesis of cDNA was done by the application of a programmable thermocycler for 55 min at 45 °C; which was then incubated for 3 min at 95°C. Finally, equilibrium was reached at 20 °C for 1 min.

Primer design

The Oligo7 and Primer Explorer V.4 software were utilized to design RT-PCR and RT-LAMP specific primers based on the human prostate specific antigen gene (GenBank: M27274.1) (**Table 1**). They were subsequently examined based on sequence alignments using ClustalX 2.11 (Des Higgins). The positions of the designed primers on the sequence are displayed in **Figure 1A**.

RT-PCR assay

RT-PCR amplification was carried out in a thermocycler (iCycler, BIO RAD, CA, USA) using cDNA. The cDNA was incubated at 95 °C for 3 min and then chilled on ice for 3 min. Amplification was done in a volume of 25 µl containing 10 × PCR buffer (10 mM Tris-HCl, pH 8.3 and 50 mM KCl), 1.5 mM MgCl₂ (CinnaGen Co., Iran), 0.5 µM each of F and B primers, 0.2 mM of dNTPs (CinnaGen Co., Iran), 2 U of Taq DNA polymerase (CinnaGen Co., Iran) and 2 µl template cDNA. Amplification was performed with the following PCR profile: 3 min at 94 °C (1 cycle); 35 cycles of 1 min at

Table 1. Details of primers derived from human prostate specific antigen gene of PSA

Primer	Position on gene	Length	Sequence(5-3)
F	555-572	18 nt	TCAGCCTCTGGGTGCCAG
B	979-996	18 nt	TTCCCCTTTAGTAAAGCA
B3	902-921	20 nt	GTGTCACCATGTGGGTCCCG
FIP (F1c and F2)	755-776 and 714-735	48 nt	TGACAGTCAGGGCTGGCTCCCTTTTGGATTGGTGAGAGGGGCCATG
BIP (B1c and B2)	797-818 and 759-780	48 nt	AACCCAGCACCCAGCCAGACTTTTGGGGGCTGGGGGTATGGGCTT





Figure 1. Position of oligonucleotide primers used for detection of the PSA (A). Results of electrophoresis of RT-PCR products (B). M, DNA size marker (100 bp); lanes 1-15 (localized cancer samples); lanes 16-30 (metastatic cancer samples); lanes 31-38 (BPH samples); lane 39 (negative control: female); lane 40 (negative control: male); lane 41 (positive control: PC3) and lane 42 (positive control: LNCaP).

94 °C, 1 min at 54 °C, 1 min at 72 °C and 10 min at 72 °C for final extension. RT-PCR products were visualized by staining with ethidium bromide after electrophoresis on 1% agarose gel. Finally, using a UV transilluminator (GELDOC 2000, Bio-Rad, USA) a photo of each gel containing RT-PCR fragments (expected size 442 bp) was produced.

Optimization of reaction and RT-LAMP assay

The mentioned positive control was employed to examine and optimize the impacts of temperature, time, dNTP, betaine, and Bst DNA polymerase concentrations. Afterwards, the isolated cDNA underwent an RT-LAMP reaction. The cDNA was incubated at 95 °C for 3 min and chilled on ice for 3 min. 3 µl of cDNA as the template in the RT-LAMP total volume (25 µl) contained 20 mM Tris-HCl (pH 8.8), 10 mM (NH4)-2SO4, 10 mM KCl, 2 mM Betaine (Sigma-Aldrich, Oakville, Ontario, Canada), 0.1% Triton X-100, 10 mM each of dNTP, 0.8 µM each of FIP and BIP, 0.2 µM each of F3 and B3 and 4 U of Bst DNA polymerase (New England Biolabs Inc.). After incubating the mixture in a water bath at 62 °C for 60 min, segregation of the products was conducted using electrophoresis on a 1.5% agarose gel. Also, prior to the amplification, 1

µl of the GeneFinder™ (Biov. Bio. Xiamen, China), was added to the RT-LAMP master mix to provide a visual detection of the RT-LAMP products. The color change occurring in the tubes (positive reaction) from red (prior to amplification) to green (post-amplification) was monitored by visual observation.

Sensitivity of the assay

Comparison of the sensitivity of the detection methods was carried out using the cDNA of the positive control (a tenfold dilution from 1 × 10¹⁰ to 1 × 10¹).

RESULTS:

PSA was detected in samples and positive controls by RT-PCR and the predicted DNA fragment (304 bp) was observed on agarose gel (**Figure 1B**). 28 patients (out of 30 prostate cancer patients) were suffering from localized and the rest from metastatic prostate cancer. No sign of PSA was observed by RT-PCR in the samples derived from healthy individuals and those with BPH. Nevertheless, as **Table 2** shows, metastatic (100%) and localized prostate cancer patients (86.6%) and positive controls had PSA transcripts. In brief, both the control subjects and BPH were reported negative by RT-PCR. The effects of temperature and time, as well as the con-

Table 2. Correlation between PSA, clinical and pathological results

Classification of Patients	Total		Positive		Negative	
	No	%	No	%	No	%
Localized cancer	15	86.6	13	86.6	2	13.4
Metastatic cancer	15	100	15	100	0	0
Benign prostate hyperplasia (BPH)	15	0	0	0	15	100
Negative control (men)	1	0	0	0	1	100
Negative control (women)	1	0	0	0	1	100
Positive control (PC3)	1	100	1	100	0	0
Positive control (LNCaP)	1	100	1	100	0	0
Total	49	61.22	30	61.22	19	38.78

centrations of dNTP, Bst DNA polymerase and Betaine were examined. Temperature range was considered between 58-68 °C. The results showed that amplification occurred at 60 to 64-65 °C (**Figure 2A**). Moreover, the minimum time for completion of the reaction was 40 min (**Figure 2B**). To test the effects of dNTP concentration on LAMP reaction, final concentration of 1 mM to 10 mM was prepared. The results showed that at 7 mM to 10 mM, ladder-like DNA fragments were clearly visible (**Figure 2C**). Different concentrations (1 U to 10 U) of Bst DNA polymerase were used to select minimum concentrations with good performance. With a low concentration of enzyme (3U), poor amplification of DNA was observed, but by increasing the enzyme concentration to 4 U, and further up until 10

U, amplification was considerably improved (**Figure 2D**). The effect of a Betaine concentration from 5 mM to 1000 mM was examined. When the concentration of Betaine was increased from 5 mM to 75 mM, the intensity of the amplified products increased but, no visible products were detected when the concentration was increased to 200 mM (**Figure 2E**).

After achieving optimal conditions and testing 47 samples via RT-LAMP assay, a large number of DNA fragments were observed in a ladder-like pattern by electrophoresing the amplicons on 1.5% agarose gel (**Figure 3A**). It was possible to see the amplicons with the naked eye by detecting color changes in the solutions with the help of various visual dyes. Positive (green) and negative (red) samples could be clearly




Figure 2. Results of optimization of RT-LAMP reaction. Effects of temperature (A), effects of the reaction time (B), effects of dNTP concentration (C), effects of Bst DNA polymerase concentrations (D), effects of Betaine concentrations (E) and DNA size marker (100 bp) (M).

and successfully distinguished from each other using GeneFinder™.

RT-LAMP assay yielded products with even lower concentration of sap dilutions (1×10^2 or more), whilst RT-PCR required a higher concentration (1×10^5 or more) (**Figure 3B**). RT-LAMP assay had a higher sensitivity for the detection of PSA in comparison with RT-PCR (1000-fold).

DISCUSSION:

The serum PSA screening test has revolutionized the early detection of CaP, but the high false-positive rate of the PSA test has led to unnecessary biopsies, a matter that has caused concern²¹. With the enormous increase in the rate of CaP incidence, the review of current practices for screening, diagnosis, and staging have been highly investigated²². The majority of new CaP cases are clinically localized without obvious metastases. However, 30-40% patients show biochemical recurrence after treatment of localized disease²³. It is apparent that accurate detection, staging, and prognostic tools are needed, since many CaP patients are not cured by local therapies due to the existence of occult micro-metastases. Diverse technological approaches have been used to evaluate the presence of circulating PSA-expressing cells (CPECs) or tumor DNA in the peripheral blood of CaP patients. Analysis of CPECs in the blood of CaP patients has been performed through cytokeratin-immunomagnetic isolation²⁴. Qualitative characterization of CPECs can be achieved through magnetic cell sorting and immunocytochemistry²⁵. Additional studies on CPECs by density gradient centrifugation and immunomagnetic bead selection of epithelial cells from peripheral blood have been carried out by several groups^{26,27}. Other techniques for CPEC isolation such as using ammonium chloride and distilled water erythrocyte lysis have been tested; however, isolation through density gradient separation and Ber-EP4 immunocapture are more sensitive and efficient²⁸.

Analysis through flow cytometry on immunomagnetic-enriched epithelial cells was also investigated; however, sensitivity and specificity were limited because of the nature and technique of specimen collection²⁹. Studies on methylation-specific PCR targeting promoter hypermethylation of the glutathione S-transferase P1 gene for the possible molecular detection of CPECs have been performed on various human bodily fluids, including plasma, serum, urine, and blood. Glutathione S-transferase P1 promoter hypermethylation was found in 90% of tumors, 72% of plasma or serum samples, and 76% of urine specimens³⁰. However, the nature and origin of the circulating DNA tested by methylation-specific PCR has not been defined. The ability to detect small numbers of CPECs by sensitive RT-PCR-based methods, despite current limitations, represents the potential of molecular technology in aiding the detection and staging of CaP^{1,4,6}.

Peripheral blood-based RT-LAMP assay was applied to investigate PSA in Iranian prostate cancer patients compared to BPH patients in the present research; healthy individuals were also entered as control subjects. Similar results were obtained in a preliminary evaluation by RT-PCR assay. Here, the products amplified via RT-LAMP could be readily visualized with the help of color indicators without any additional staining systems involving toxic materials. Even though RT-LAMP and RT-PCR techniques had enough potential to differentiate and detect infected samples accurately, RT-LAMP proved to be more useful after considering overall time, safety, cost and user friendliness (**Table 3**). Contrary to the proposed approach displaying the advantages of simplicity, user-friendly, and cost-effectiveness, any other methods for PSA detection, require professional personnel to work in labs equipped with costly molecular instruments¹⁷. Furthermore, no thermocyclers and gel electrophoresis were needed for accomplishing LAMP assay as it could be easily conducted in a water bath or through temperature block¹⁹.




Figure 3. Results of RT-LAMP assay by electrophoresis of products and reaction tube (A) and comparison of sensitivity using a ten dilution series (B). M, DNA size marker (100 bp); lanes 1-15, (localized cancer samples); lanes 16-30, (metastatic cancer samples); lanes 17-45, (BPH samples); lane 46, (negative control: female); lane 47, (negative control: male); lane 48, (positive control: PC3) and lane 49, (positive control: LNCaP).

Table 3. Comparison of RT-PCR and RT-LAMP assays

Assay	amplification time	Detection method	Safety	Need to UV ray	Need to detect instruments	Cost	User Friendly	Sensitivity
RT-PCR	180 min	Gel electrophoresis	No	Yes	Yes	High	High	10 ⁵
RT-LAMP	30 min	Visual/Gel electrophoresis	Yes/No	No/Yes	No/Yes	Low	Very high	10 ²

Generally, the need for additional staining for pursuing post-amplification processes can be obviated by making easier and quicker visual detections via RT-LAMP in-tube color indicator¹⁶. It is worth noting that in contrast to colorimetric-based methods, GeneFinder™ dye-based assays are more advantageous due to their involving addition prior to amplification; therefore there is no need to open the assayed samples, decreasing the risk of sample contamination^{17,18}.

CONCLUSION:

In this research, RT-LAMP positive amplicons were observed with the naked eye by adding fluorescent dye to the reaction tubes. Conclusively, cross-contamination risks would be reduced by using and adding GeneFinder™ dye to the reaction mixture before amplification without the need to open the assayed samples. Hence, RT-LAMP assay has several remarkable advantages over any other colorimetric-based methods and can serve as a suitable approach not only to the laboratory detection of PSA, but also to field diagnoses of molecular epidemiology research.

ACKNOWLEDGMENT:

The author is grateful to the Young Researchers and Elites Club, North Tehran Branch, Islamic Azad University, Tehran, Iran for financial support for this study.

CONFLICTS OF INTEREST:

All authors declared no conflict of interest.

REFERENCES:

1. Seiden MV, Kantoff PW, Krithivas K, Propert K, Bryant M, Haltom E, Gaynes L, Kaplan I, Bublely G, DeWolf W, Sklar J. Detection of circulating tumor cells in men with localized prostate cancer. *Journal of Clinical Oncology*. 1994 Dec 1;12(12):2634-9.
2. Boring CC, Squires TS, Tong T. *Cancer statistics, 1994*. CA: a cancer journal for clinicians. 1994;44(1):7-26.
3. Wingo PA, Landis S, Ries LAG. An adjustment to the estimate for new prostate cancer cases. *CA A cancer J Clin*. 1997;80:1810-13.
4. Daher R, Beaini M. Prostate-specific antigen and new related markers for prostate cancer. *Clinical chemistry and laboratory medicine*. 1998 Sep 1;36(9):671-81.
5. Landis SH, Murray T, Bolden S, Wingo PA. *Cancer statistics, 1999*. CA: A cancer Journal for Clinicians. 1999 Jan;49(1):8-31.
6. Gao CL, Rawal SK, Sun L, Ali A, Connelly RR, Banez LL, Sesterhenn IA, Mcleod DG, Moul JW, Srivastava S. Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients. *Clinical cancer research*. 2003 Jul 1;9(7):2545-50.
7. Gewanter RM, Katz AE, Olsson CA, Benson MC, Singh A, Schiff PB, Ennis RD. RT-PCR for PSA as a prognostic factor for patients with clinically localized prostate cancer treated with radiotherapy. *Urology*. 2003 May 1;61(5):967-71.
8. Lundwall Å, Lilja H. Molecular cloning of human prostate specific antigen cDNA. *FEBS letters*. 1987 Apr 20;214(2):317-22.
9. Shariat SF, Kattan MW, Song W, Bernard D, Gottenger E, Wheeler TM, Slawin KM. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. *Cancer research*. 2003 Sep 15;63(18):5874-8.
10. Wang TJ, Rittenhouse HG, Wolfert RL, Lynne CM, Brackett NL. PSA concentrations in seminal plasma. *Clinical chemistry*. 1998 Apr 1;44(4):895a-6.
11. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. *The Journal of clinical investigation*. 1985 Nov 1;76(5):1899-903.

12. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. *New England Journal of Medicine*. 1987 Oct 8;317(15):909-16.
13. Brawer MK, Peehl DM, Stamey TA, Bostwick DG. Keratin immunoreactivity in the benign and neoplastic human prostate. *Cancer research*. 1985 Aug 1;45(8):3663-7.
14. Israeli RS, Miller WH, Su SL, Powell CT, Fair WR, Samadi DS, Huryk RF, DeBlasio A, Edwards ET, Wise GJ, Heston WD. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. *Cancer research*. 1994 Dec 15;54(24):6306-10.
15. Moreno JG, Croce CM, Rischer R, Monne M, Vihko P, Mulholland SG, Gomella LG. Detection of hematogenous micrometastasis in patients with prostate cancer. *Cancer Research*. 1992 Nov 1;52(21):6110-2.
16. Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K, Amino N, Hase T. Loop-mediated isothermal amplification of DNA. *Nucleic acids research*. 2000 Jun 15;28(12):e63-.
17. Mori Y, Kitao M, Tomita N, Notomi T. Real-time turbidimetry of LAMP reaction for quantifying template DNA. *Journal of biochemical and biophysical methods*. 2004 May 31;59(2):145-57.
18. Tsai SM, Chan KW, Hsu WL, Chang TJ, Wong ML, Wang CY. Development of a loop-mediated isothermal amplification for rapid detection of orf virus. *Journal of Virological Methods*. 2009 May 1;157(2):200-4.
19. Almasi MA, Erfan Manesh M, Jafary H, Dehabadi SM. Visual detection of Potato leafroll virus by one-step reverse transcription loop-mediated isothermal amplification of DNA with the Genefinder™ dye. *J Virol Methods*. 2003;192:51-4.
20. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Analytical biochemistry*. 1987 Apr 1;162(1):156-9.
21. Barry MJ. Prostate-specific-antigen testing for early diagnosis of prostate cancer. *New England Journal of Medicine*. 2001 May 3;344(18):1373-7.
22. Garnick MB, Fair WR. Combating prostate cancer. *Scientific American*. 1998 Dec 1;279(6):74-83.
23. MOUL JW. Prostate specific antigen only progression of prostate cancer. *The Journal of urology*. 2000 Jun;163(6):1632-42.
24. Brandt B, Junker R, Griwatz C, Heidl S, Brinkmann O, Semjonow A, Assmann G, Zänker KS. Isolation of prostate-derived single cells and cell clusters from human peripheral blood. *Cancer research*. 1996 Oct 15;56(20):4556-61.
25. Wang ZP, Eisenberger MA, Carducci MA, Partin AW, Scher HI, Ts'o PO. Identification and characterization of circulating prostate carcinoma cells. *Cancer*. 2000 Jun 15;88(12):2787-95.
26. Moreno JG, O'Hara SM, Gross S, Doyle G, Fritsche H, Gomella LG, Terstappen LW. Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. *Urology*. 2001 Sep 1;58(3):386-92.
27. Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LW, Uhr JW. Detection and characterization of carcinoma cells in the blood. *Proceedings of the National Academy of Sciences*. 1998 Apr 14;95(8):4589-94.
28. Sabile A, Louha M, Bonte E, Poussin K, Vona G, Mejean A, Chretien Y, Bougas L, Lacour B, Capron F, Roseto A. Efficiency of Ber-EP4 antibody for isolating circulating epithelial tumor cells before RT-PCR detection. *American journal of clinical pathology*. 1999 Aug 1;112(2):171-8.
29. Muscatelli B, Colombel M, Jouault H, Amsellem S, Mazeman E, Abbou CC, Chopin D. In vitro detection of prostate cancer circulating cells by immunocytochemistry, flow cytometry and RT-PCR PSA. *Progres en urologie: journal de l'Association francaise d'urologie et de la Societe francaise d'urologie*. 1998 Dec;8(6):1058-64.
30. Goessl C, Müller M, Heicappell R, Krause H, Miller K. DNA-based detection of prostate cancer in blood, urine, and ejaculates. *Annals of the New York Academy of sciences*. 2001 Sep;945(1):51-8.